huCART19-IL18

N/A

Report date: 2023/08/21 14:57:50

Base Information

Drug NamehuCART19-IL18

Drug Alias NameTmCD19-IL18TmCD19-IL18 CAR T Cells therapy(Kite Pharma)Autologous Chimeric Antigen Receptor (CAR) T cells therapy(Kite Pharma)TMhuCART19-IL18

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD19T lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of Pennsylvania Kite Pharma

China Registration ClassN/A

Develop Information

Active CompaniesKite Pharma University Of Pennsylvania

Inactive CompaniesN/A

Active IndicationsLymphoma, Non-HodgkinPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Lymphocytic, Chronic, B-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A